Risk factors for severe low anterior resection syndrome in patients with rectal cancer undergoing sphincter-preserving resection: A systematic review and meta-analysis

LU-LU XU[1], TIAN-CHENG CHENG[1], NENG-JUN XIANG[1], PENG CHEN[1], ZHI-WEI JIANG[2] and XIN-XIN LIU[2]

[1]The First Clinical Medical College, Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210023;
[2]Department of General Surgery, Jiangsu Provincial Hospital of Traditional Chinese Medicine Affiliated to
Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China

Abstract. The present study aimed to evaluate the incidence and risk factors of severe low anterior resection syndrome (LARS) in patients with rectal cancer undergoing sphincter-preserving resection, and to provide the clinical basis and reference for the treatment of rectal cancer and the prevention of LARS. Studies on the incidence and risk factors for severe LARS in patients with rectal cancer undergoing sphincter-preserving resection were searched using PubMed, Embase, Cochrane Library, Scopus and Web of Science, according to the inclusion and exclusion criteria. After evaluating the study quality and extracting relevant data, RevMan 5.2 and STATA software were used to conduct a meta-analysis. A total of 12 articles were considered eligible for the present meta-analysis. Within these articles, there were 3,877 cases of sphincter-preserving resection for rectal cancer and 1,589 cases of severe LARS; the incidence of severe LARS was 40.99%. The results of the meta-analysis revealed that sex [female; odds ratio (OR), 6.54; 95% CI, 3.63-11.76; Z, 6.27; P<0.00001], radiotherapy and chemotherapy (OR, 3.45; 95% CI, 2.29-5.21; Z, 5.91; P<0.00001), total mesorectal excision (TME; OR, 4.39; 95% CI, 3.32-5.79; Z, 10.41; P<0.00001), and distance between tumor and anal margin (OR, 2.74; 95% CI, 0.86-8.72; Z, 1.70; P<0.00001) may be the risk factors for severe LARS.

Correspondence to: Dr Xin-Xin Liu, Department of General Surgery, Jiangsu Provincial Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Traditional Chinese Medicine, 155 Hanzhong Road, Qinhuai, Nanjing, Jiangsu 210029, P.R. China
E-mail: 20210444@njucm.edu.cn

Introduction

Rectal cancer is a type of malignant tumor of the digestive tract. Although the overall incidence of rectal cancer is slowly decreasing year by year, the incidence in adults <65 years old is still increasing (1). Most patients with rectal cancer have low rectal cancer (tumor distance from anus <5 cm) (2). Abdominoperineal resection (Miles operation) has been used to treat low rectal cancer; however, patients require permanent abdominal wall fistulation following the operation. Although this operation can achieve local radical resection of the tumor, a permanent stoma in the abdominal wall can affect the postoperative life of patients. Miles operation has a marked influence on some normal functions of patients after operation, such as defecation, voiding and sexual functions (3). With the development of surgical instruments and the improvement of surgical technology, clinicians have aimed to identify methods to cure tumors and preserve the anus (4). To protect the anus, total mesorectal excision (TME), intersphincteric resection and anterior resection have been widely used. With the progression of surgical approaches, it is now possible to perform sphincter-preserving resection (SPR) on patients with low rectal cancer. However, novel problems have also emerged, with 60-90% of patients with rectal cancer experiencing defecation disorders after SPR. These disorders are known as low anterior resection syndrome (LARS) (5). LARS may reduce the quality of life of patients after operation, and severe LARS will negatively affect the daily life of patients (6). Currently, there is no specific treatment for LARS, and most of the treatments are symptomatic; therefore, the prevention of LARS is necessary (7). Notably, accurate prediction of the influencing factors of LARS is of great significance in reducing the incidence of LARS. Numerous theories on the pathogenesis and influencing factors of LARS have been put forward; however, there are some problems, such as small sample size, incomplete research projects, inconsistent research results, lack of convincing research results and lack of in-depth research (8). Therefore, the present study performed a meta-analysis to systematically evaluate the studies on the influencing factors of LARS in rectal cancer, with the aim of identifying accurate and reliable influencing factors of LARS and providing a

theoretical basis and reference for clinical work, to reduce the incidence of LARS.

Materials and methods

Literature source. Studies on the efficacy of the risk factors for severe LARS in patients with rectal cancer undergoing sphincter-preserving surgery were searched using PubMed (https://pubmed.ncbi.nlm.nih.gov/), Embase (www.embase.com), Cochrane Library (https://www.cochranelibrary.com/), Scopus (https://www.scopus.com/) and Web of Science (https://www.webofscience.com/). The studies published in these databases between January 1, 2000 and December 31, 2022 on the influencing factors of LARS in patients with rectal cancer undergoing sphincter-preserving surgery were searched.

Search strategy. A systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines (9). The search strategy was carried out in the databases based on the search string: [(Rectal Neoplasms (Medical Subject Headings, MeSH Terms)) OR (Rectal Tumor (MeSH Terms)) OR ((MeSH Tumor, Rectal Terms)) OR (Neoplasms (MeSH Terms)) OR (Cancer of Rectum (MeSH Terms))] AND [(Anterior resection syndrome) OR (Fecal incontinence) OR (Postoperative complication) OR (LARS) OR (Low Anterior Resection Syndrome)] AND [Radiofrequency ablation] AND [(Influencing factors) OR (Interfering factors)]. All detected studies were assessed for eligibility.

Literature inclusion criteria. The inclusion criteria were as follows: i) Published literature on the related influencing factors of severe LARS for patients with rectal cancer; ii) all articles used the LARS score (6) to evaluate severe LARS (LARS score >29) and its risk factors; iii) all subjects were patients with rectal cancer diagnosed by colonoscopy and pathology before operation; iv) there was no defecation dysfunction or pelvic surgery history before the operation; v) the research results described odds ratio (OR) and 95% CI values, or OR and 95% CI could be calculated using the literature data; and vi) Newcastle Ottawa scale (NOS) (10) score ≥6 points.

Literature exclusion criteria. The exclusion criteria were as follows: i) Reviews, animal studies, preliminary reports of research, case reports, letters to editors, meeting minutes, commentaries and studies published in languages other than English; ii) published in repeated publications in different databases; iii) the purpose of the study was not defined, and/or the data were not detailed or inconsistent; and iv) the diagnosis of the patient was not clear, and the LARS score was not used for LARS diagnosis in the article.

Literature screening and data extraction. According to the unified retrieval strategy, two independent researchers retrieved and imported the studies into EndNote 21 software (https://endnote.com/). Literature screening, data extraction and risk of bias assessment were all carried out by two reviewers independently. Conflicts were resolved by a third independent reviewer. The EndNote software automatically deleted reviews, animal experiments, repetitive literature, case


Figure 1. Literature screening process and results. LARS, low anterior resection syndrome.

reports and literature published prior to 2000. All studies were read and the literature was excluded if it contained inconsistent research content, incorrect research methods (diagnosis of the case was not clear and LARS was not diagnosed using the LARS score) or no extractable data that met the inclusion criteria. The sample size, the source of patients, the research methods, and the factors affecting the incidence and occurrence of LARS were extracted from the studies.

Quality evaluation. The quality of the literature was evaluated according to the NOS scale (10). The case-control NOS scale was scored based on three aspects: Case group and control group selection, comparability and exposure. There were eight scoring conditions, with a total score of 9. Literature with a score of ≥7 was considered high-quality, whereas that with a score of ≤4 was considered low-quality literature.

Statistical analysis. Data for meta-analysis were entered into MS Excel 2019 (Microsoft Corporation). Meta-analysis was carried out using RevMan 5.2 (The Cochrane Collaboration)

Table I. Basic information of the included literature.

First author/s, year	Country	Study design	Sample size	Severe LARS cases	NOS score	Influencing factors	(Refs.)
Bondeven et al, 2015	Denmark	Retrospective	125	47	8	1	(12)
Bregendahl et al, 2013	Denmark	Retrospective	938	383	8	1,2,3,4	(13)
Cheong et al, 2019	South Korea	Prospective	203	106	7	1,2	(14)
Ekkarat et al, 2016	Thailand	Retrospective	129	23	6	1	(15)
Emmertsen et al, 2013	Denmark	Retrospective	193	84	9	1,4	(16)
Jimenez-Gomez et al, 2017	Spain	Cross sectional	184	104	9	1,4	(17)
Lynes and Thaha, 2016	UK	Retrospective	1,093	447	8	1,2	(18)
Qin et al, 2017	China	Cross sectional	142	63	8	1,5	(19)
Sun et al, 2019	China	Retrospective	129	60	8	2	(20)
Hughes et al, 2017	UK	Retrospective	68	38	6	1	(21)
van Heinsbergen, 2018	Netherlands	Retrospective	412	141	7	2,5	(22)
Kupsch et al, 2018	Germany	Retrospective	261	93	6	5	(23)

1, Radiotherapy and chemotherapy; 2, sex; 3, anastomotic leakage; 4, total mesorectal excision/partial mesorectal excision; 5, distance between tumor and anal margin. LARS, low anterior resection syndrome; NOS, Newcastle Ottawa scale.

and STATA (version 14.0; StataCorp LLC) software. Forest plots were drawn using RevMan 5.2 software. P<0.05 was considered to indicate a statistically significant difference. Q test and I^2 test were used to determine the heterogeneity of the results. The random-effects models were used to pool the effect estimates in this meta-analysis. The publication bias was assessed using a Begg's funnel chart using STATA (11). The source of heterogeneity was identified by sensitivity analysis or subgroup analysis. The sensitivity analysis was carried out using a random-effects model. Heterogeneity was evaluated by the Cochran's Q test and I^2 statistic. $I^2 \geq 50\%$ indicated greater heterogeneity. Subgroup analysis was created to explore the source of heterogeneity. Subgroup analysis was based on the study population, measurement method, number of adjusted variables and study quality.

Results

Literature retrieval results. A total of 398 original pieces of literature were obtained, all of which were imported into the EndNote 21 software; 69 records were excluded by repetition checking, 167 studies were excluded as they were reviews or meta-analyses, and 72 articles published before 2000 were excluded. The abstracts of the remaining literature were preliminarily screened, 50 articles that were not consistent with the research contents were excluded, and the remaining 40 articles were left after preliminary screening. After reading the complete text, eight repetitive studies, five articles with inconsistent research contents, seven articles with unextractable data, four articles with inconsistent research methods and statistical methods, and four articles without LARS scores were excluded. A total of 12 articles were included for quality evaluation (Fig. 1).

Essential characteristics of the included literature. A total of 12 articles were included in the present meta-analysis. The

cases were from eight countries: China, Denmark, South Korea, Thailand, Spain, UK, Netherlands and Germany (12-23). A total of 3,877 patients were included in the study, of which 1,589 patients had severe LARS (Table I). The factors that could affect the incidence of LARS were numbered and outlined. The basic information of the included studies is shown in Table I.

Quality evaluation of the included literature. The quality of the 12 articles that met the criteria for inclusion in the present meta-analysis was evaluated. After quality evaluation, nine high-quality articles with a NOS score of ≥7 and three articles with a NOS score of 6 were obtained (Table I).

Effect of radiotherapy and chemotherapy on severe LARS in rectal cancer. A total of 10 studies reported on the association between radiotherapy and chemotherapy and severe LARS (Table II). The forest plot of the random-effects meta-analysis of the effect of radiotherapy and chemotherapy on severe LARS in rectal cancer is shown in Fig. 2 (OR, 3.45; 95% CI, 2.29-5.21; Z, 5.91; P<0.00001). Sensitivity analysis was carried out to assess the stability of the results. No significant variations were observed when eliminating any one article. According to whether only radiotherapy was used as the standard, the eligible articles were divided into only radiotherapy and non-only radiotherapy subgroups. The results of the subgroup analysis are shown in Fig. 3. The heterogeneity of only radiotherapy articles was $I^2=83\%$, P=0.003. The heterogeneity of non-only radiotherapy articles was $I^2=89\%$, P<0.00001. These findings indicated that radiotherapy and chemotherapy were risk factors for severe LARS, and the radiotherapy alone group had a higher risk of LARS than the non-only radiotherapy group. A Begg's funnel map was used to perform publication bias analysis for radiotherapy and chemotherapy (Fig. 4). The results indicated that there was a particular publication bias, but the bias was slight.

Table II. Radiotherapy and chemotherapy as risk factors for severe LARS.

First author/s, year	Risk factors	OR	OR_LL	OR_UL	(Refs.)
Bondeven et al, 2015	Neoadjuvant therapy (yes/no)	3.50	1.15	9.40	(12)
Bregendahl et al, 2013	Neoadjuvant therapy (yes/no)	2.48	1.73	3.55	(13)
Cheong et al, 2019	Chemoradiation (yes/no)	3.89	2.98	16.60	(14)
Ekkarat et al, 2015	Radiation therapy (yes/no)	6.50	2.37	3.55	(15)
Emmertsen et al, 2013	Neoadjuvant therapy (yes/no)	2.41	1.00	5.83	(16)
Hughes et al, 2017	Neoadjuvant treatment (radiotherapy) (yes/no)	19.90	3.50	113.10	(21)
Jimenez-Gomez et al, 2017	Postoperative radiotherapy (yes/no)	9.52	1.74	3.00	(17)
Lynes and Thaha, 2016	Neoadjuvant chemoradiotherapy (yes/no)	3.89	2.49	6.07	(18)
Qin et al, 2017	Neoadjuvant therapy (NCRT/NCT)	5.13	2.29	11.49	(19)
Sun et al, 2019	Neoadjuvant therapy (NCRT/NCT)	2.20	1.24	3.91	(20)

The OR data were calculated in the previous studies. NCRT, neoadjuvant radiochemotherapy; NCT, neoadjuvant chemotherapy; OR, odds ratio; LL, long long; UL, unsigned long.


Figure 2. Forest plot of the random-effects meta-analysis of the effect of radiotherapy and chemotherapy on severe LARS in rectal cancer. df, degrees of freedom; LARS, low anterior resection syndrome; M-H, Mantel-Haenszel; experimental, LARS group; control, Control group.

Effect of sex on severe LARS in rectal cancer. A total of four studies reported on the association between sex and the incidence of severe LARS, and the random-effects model was used to examine the effects of sex on severe LARS. As shown in Fig. 5, the heterogeneity was apparent: I^2=94%, P<0.00001. Through sensitivity analysis, it was revealed that Cheong et al (14) was the source of heterogeneity, and the forest plot of the random-effects meta-analysis after elimination is shown in Fig. 6. The results revealed that the risk of severe LARS in female patients was slightly higher (OR, 6.54; 95% CI, 3.63-11.76; Z, 6.27; P<0.00001).

Effect of TME on severe LARS in rectal cancer. A total of four articles reported the relationship between TME and severe LARS. The forest plot of the random-effects meta-analysis showed a significant association between TME and the incidence of severe LARS (OR, 4.39; 95% CI, 3.32-5.79; Z, 10.41; P<0.00001; Fig. 7). These findings indicated that TME was an influencing factor of severe LARS in rectal cancer.

Effect of distance between tumor and anal margin on severe LARS in rectal cancer. Two articles reported on the relationship between the distance between the tumor and anal margin and severe LARS. The forest plot of the random-effects meta-analysis showed that there was a significant association between the distance between the tumor and anal margin and severe LARS (OR, 2.74; 95% CI, 0.86-8.72; Z, 1.70; P<0.00001; Fig. 8). These findings suggested that the distance between the tumor and anal margin was an influencing factor of severe LARS in rectal cancer.

Discussion

Numerous studies have reported on the influencing factors of postoperative LARS in rectal cancer; however, the results vary (24,25). The present study collected literature on the influencing factors of severe LARS in rectal cancer between January 1, 2000 and December 31, 2020, and systematically analyzed the association between the influencing factors and

Study or subgroup	LARS Events	Total	Control Events	Total	Weight	Odds ratio M-H, Random, 95% CI	Odds ratio M-H, Random, 95% CI
Only radiotherapy							
Ekkarat *et al*, 2015 (15)	23	129	15	129	8.9%	1.65 [0.82, 3.33]	
Hughes *et al*, 2017 (21)	38	68	14	50	8.4%	3.26 [1.49, 7.11]	
Jimenez *et al*, 2017 (17)	104	184	28	184	10.4%	7.24 [4.41, 11.90]	
Subtotal (95% CI)		381		363	27.7%	3.48 [1.39, 8.72]	
Total events	165		57				
Heterogeneity: Tau²=0.54; Chi²=11.83, df=2 (P=0.003); I²=83%							
Test for overall effect: Z=2.66 (P=0.008)							
Radiotherapy and chemotherapy							
Bondeven *et al*, 2015 (12)	47	125	20	125	9.7%	3.16 [1.74, 5.76]	
Bregendahl *et al*, 2013 (13)	383	938	123	780	11.9%	3.69 [2.92, 4.65]	
Cheong *et al*, 2019 (14)	106	203	78	203	11.1%	1.75 [1.18, 2.60]	
Emmertsen *et al*, 2013 (16)	84	193	30	193	10.5%	4.19 [2.59, 6.78]	
Lynes *et al*, 2016 (18)	447	1093	46	682	11.5%	9.57 [6.93, 13.21]	
Qin *et al*, 2017 (19)	60	129	20	129	9.8%	4.74 [2.63, 8.54]	
Sun *et al*, 2019 (20)	38	68	14	30	7.8%	1.45 [0.61, 3.43]	
Subtotal (95% CI)		2749		2142	72.3%	3.57 [2.21, 5.75]	
Total events	1165		331				
Heterogeneity: Tau²=0.35; Chi²=52.34, df=6 (P<0.00001); I²=89%							
Test for overall effect: Z=5.22 (P<0.00001)							
Total (95% CI)		3130		2505	100.0%	3.56 [2.39, 5.29]	
Total events	1330		388				
Heterogeneity: Tau²=0.33; Chi²= 64.12, df=9 (P<0.00001); I²=86%							
Test for overall effect: Z=6.27 (P<0.00001)							
Test for subgroup differences: Chi²=0.00, df=1 (P=0.96), I²=0%							

0.01 0.1 1 10 100
Favors experimental Favors control

Figure 3. Subgroup analysis of the effect of radiotherapy and chemotherapy on severe LARS in rectal cancer. df, degrees of freedom; LARS, low anterior resection syndrome; M-H, Mantel-Haenszel; experimental, LARS group; control, Control group.


Figure 4. Begg's funnel map showing the publication bias analysis for radiotherapy and chemotherapy. A previous study has found that among the factors that affect the incidence of severe low anterior resection syndrome, radiotherapy and chemotherapy is an important factor (39). Therefore, the bias analysis was performed for the radiotherapy and chemotherapy factor. OR, odds ratio; SE, standard error.

the incidence of LARS. The meta-analysis results demonstrated that female sex, radiotherapy and chemotherapy, distance between the tumor and anal margin, and TME were the influencing factors of severe LARS in rectal cancer.

Tanaka *et al* (26) conducted a 5-year follow-up study on 506 patients with rectal cancer following anus-preserving surgery. The results revealed that female patients had a higher risk of developing LARS than male patients. The present results showed that the risk of LARS in women was higher than that in men, which was consistent with the results of this previous

study. This may be because the anal sphincter of women is congenitally thinner than that in men, and most patients with rectal cancer are elderly patients. Most female elderly patients have a reproductive history; natural delivery through the birth canal can relax the pelvic floor muscles, which may be why the risk of LARS in female patients is higher than that in men (27). Furthermore, there are intrauterine organs in the female pelvis, which reduces the functional space during the operation to a certain extent (28). If the surgical technique is unsuccessful, it can increase the injury of the pelvic autonomic nerve and anal sphincter (29).

With the development of radiotherapy and chemotherapy, patients with colorectal cancer have a higher resection rate, sphincter preservation success rate, survival rate and clinical cure rate (30). However, the present meta-analysis found that radiotherapy and chemotherapy could increase the incidence of severe LARS. After subgroup analysis, it was observed that the radiotherapy alone group (OR=3.48) had a higher risk of LARS than the radiotherapy and chemotherapy group (OR=3.57). Emerging evidence has suggested that the incidence of severe LARS after neoadjuvant radiotherapy and chemotherapy is higher than that of severe LARS after neoadjuvant chemotherapy (30,31). In addition, a recent study has demonstrated that compared with those receiving relatively simple chemotherapy, patients receiving radiotherapy and chemotherapy have a higher incidence of postoperative complications (32,33). A recent study concluded that even patients who received radiotherapy without surgery developed severe LARS, possibly because radiotherapy was more toxic than sphincter-preserving resection (31). However, radiotherapy and chemotherapy can reduce the intestinal function of patients with colorectal cancer, which may be caused by

Study or subgroup	LARS Events	Total	Control Events	Total	Weight	Odds ratio M-H, Random, 95% CI
Bregendahl *et al*, 2013 (13)	383	938	123	780	26.0%	3.69 [2.92, 4.65]
Cheong *et al*, 2019 (14)	106	203	78	203	24.7%	1.75 [1.18, 2.60]
Lynes *et al*, 2016 (18)	447	1093	46	682	25.3%	9.57 [6.93, 13.21]
van Heinsbergen *et al*, 2018 (22)	141	412	25	412	24.1%	8.05 [5.12, 12.67]
Total (95% CI)		**2646**		**2077**	**100.0%**	**4.71 [2.33, 9.55]**
Total events	1077		272			

Heterogeneity: Tau²=0.49; Chi²=52.85, df=3 (P<0.00001); I²=94%
Test for overall effect: Z=4.31 (P<0.0001)

Figure 5. Forest plot of the random-effects meta-analysis of the effect of sex on severe LARS in rectal cancer. df, degrees of freedom; LARS, low anterior resection syndrome; M-H, Mantel-Haenszel; experimental, LARS group; control, Control group.

Study or subgroup	LARS Events	Total	Control Events	Total	Weight	Odds ratio M-H, Random, 95% CI
Bregendahl *et al*, 2013 (13)	47	125	20	125	29.2%	3.16 [1.74, 5.76]
Lynes *et al*, 2016 (18)	447	1093	46	682	37.2%	9.57 [6.93, 13.21]
van Heinsbergen *et al*, 2018 (22)	141	412	25	412	33.6%	8.05 [5.12, 12.67]
Total (95% CI)		**1630**		**1219**	**100.0%**	**6.54 [3.63, 11.76]**
Total events	635		91			

Heterogeneity: Tau²=0.21; Chi²=10.30, df=2 (P=0.006); I²=81%
Test for overall effect: Z=6.27 (P<0.00001)

Figure 6. Forest plot of the random-effects meta-analysis of the effect of sex on severe LARS in rectal cancer after excluding Cheong *et al* (14). df, degrees of freedom; LARS, low anterior resection syndrome; M-H, Mantel-Haenszel; experimental, LARS group; control, Control group.

Study or subgroup	LARS Events	Total	Control Events	Total	Weight	Odds ratio M-H, Random, 95% CI
Bregendahl *et al*, 2013 (13)	383	938	123	780	38.1%	3.69 [2.92, 4.65]
Emmertsen *et al*, 2013 (16)	84	193	30	193	20.3%	4.19 [2.59, 6.78]
Jimenez *et al*, 2017 (17)	104	184	28	184	19.5%	7.24 [4.41, 11.90]
Kupsch *et al*, 2018 (23)	93	261	32	261	22.1%	3.96 [2.53, 6.20]
Total (95% CI)		**1576**		**1418**	**100.0%**	**4.39 [3.32, 5.79]**
Total events	664		213			

Heterogeneity: Tau²=0.04; Chi²=5.87, df=3 (P=0.12); I²=79%
Test for overall effect: Z=10.41 (P<0.00001)

Figure 7. Forest plot of the random-effects meta-analysis of the effect of total mesorectal excision on severe LARS in rectal cancer. df, degrees of freedom; LARS, low anterior resection syndrome; M-H, Mantel-Haenszel; experimental, LARS group; control, Control group.

Study or subgroup	LARS Events	Total	Control Events	Total	Weight	Odds ratio M-H, Random, 95% CI
Qin *et al*, 2017 (19)	60	129	20	129	53.7%	4.74 [2.63, 8.54]
van Heinsbergen *et al*, 2018 (22)	38	68	14	30	46.3%	1.45 [0.61, 3.43]
Total (95% CI)		**197**		**159**	**100.0%**	**2.74 [0.86, 8.72]**
Total events	98		34			

Heterogeneity: Tau²=0.56; Chi²=4.95, df=1 (P=0.03); I²=80%
Test for overall effect: Z=1.70 (P<0.00001)

Figure 8. Forest plot of the random-effects meta-analysis of the effect of distance between tumor and anal margin on severe LARS in rectal cancer. df, degrees of freedom; LARS, low anterior resection syndrome; M-H, Mantel-Haenszel; experimental, LARS group; control, Control group.

damage to the anal sphincter, nerves in the pelvic cavity and intestinal microecology (34).

The present study demonstrated that the distance between the tumor and the anal margin, and TME were risk factors for severe LARS. A previous study reported that when the distance from the tumor to the anal margin decreases by 1 cm, the incidence of severe LARS increases by 1.29, and patients with relatively high positions of ultra-low rectal cancer have worse intestinal function (35). It has also been reported that a residual rectal length of ≤4 cm can lead to severe intestinal

dysfunction (36). The reason may be that the lower tumor leads to a shorter residual rectal length, and the shorter rectal residue affects the rectal compliance of the patient, thus increasing the sense of urgency of defecation. Compared with traditional surgery, TME surgery reduces the local recurrence rate and the incidence of postoperative complications (37). However, TME surgery for the inferior mesenteric artery and its branches can lead to changes in residual intestinal blood supply, which may lead to intestinal dysfunction (38).

Based on the existing research, the results of the present meta-analysis were reliable but still had some limitations. First, the studies were conducted in various Asian and European countries, on patients with different ethnicities who used different languages, which may lead to differences in measurement tools, treatment options and some definitions. Second, the included literature did not mention specific radiotherapy and chemotherapy regimens, and surgical anastomoses were not introduced. There was a slight heterogeneity among the included studies, which may affect the results. Finally, more literature on other factors, such as age and anastomotic leakage, should be included; therefore, larger samples and multicenter studies are needed to clarify these factors.

In conclusion, radiotherapy and chemotherapy, TME, the distance between the tumor and anal margin, and female sex were revealed to be risk factors for severe LARS, which can seriously affect the intestinal function of patients with rectal cancer post-operation. Notably, clinicians should pay more attention to the differences in female pelvic organs during surgery and strengthen multidisciplinary cooperation to formulate more personalized radiotherapy and chemotherapy programs and surgical methods so that patients with rectal cancer have an improved intestinal function and a higher survival rate.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LLX and TCC were involved in study methodology, investigation and data curation, and wrote the original draft. PC was responsible for research design and conducted the experiments. NJX and ZWJ were responsible for data analysis, and reviewed and edited the manuscript. XXL was involved in the concepts and supervision, and reviewed and edited the manuscript. LLX and TCC confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Xiao Y, Qiu M, Huang W, Hu S, Tan C, Nan F, Jiang X, Wu D, Li M, Li Q and Qin C: Global status of research on radiotherapy for rectal cancer: A bibliometric and visual analysis. Front Public Health 10: 962256, 2022.
2. Keller DS, Berho M, Perez RO, Wexner SD and Chand M: The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol 17: 414-429, 2020.
3. Toiyama Y and Kusunoki M: Changes in surgical therapies for rectal cancer over the past 100 years: A review. Ann Gastroenterol Surg 4: 331-342, 2020.
4. Serra-Aracil X, Mora-Lopez L, Alcantara-Moral M, Caro-Tarrago A, Gomez-Diaz CJ and Navarro-Soto S. Transanal endoscopic surgery in rectal cancer. World J Gastroenterol 20: 11538-11545, 2014.
5. Annicchiarico A, Martellucci J, Solari S, Scheiterle M, Bergamini C and Prosperi P: Low anterior resection syndrome: Can it be prevented? Int J Colorectal Dis 36: 2535-2552, 2021.
6. Keane C, Fearnhead NS, Bordeianou LG, Christensen P, Basany EE, Laurberg S, Mellgren A, Messick C, Orangio GR, Verjee A, et al: International consensus definition of low anterior resection syndrome. Dis Colon Rectum 63: 274-284, 2020.
7. Varghese C, Wells CI, Bissett IP, O'Grady G and Keane C: The role of colonic motility in low anterior resection syndrome. Front Oncol 12: 975386, 2022.
8. Garfinkle R and Boutros M: Low anterior resection syndrome: Predisposing factors and treatment. Surg Oncol 43: 101691, 2022.
9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71, 2021.
10. Lo CK, Mertz D and Loeb M: Newcastle-Ottawa Scale: Comparing reviewers' to authors' assessments. BMC Med Res Methodol 14: 45, 2014.
11. Jin T, Chen ZH, Liang PP, Li ZD, He FJ, Chen ZW, Hu JK and Yang K: A Gastrectomy for early-stage gastric cancer patients with or without preserving celiac branches of vagus nerves: A meta-analysis. Surgery 173: 375-382, 2023.
12. Bondeven P, Emmertsen KJ, Laurberg S and Pedersen BG: Neoadjuvant therapy abolishes the functional benefits of a larger rectal remnant, as measured by magnetic resonance imaging after restorative rectal cancer surgery. Eur J Surg Oncol 41: 1493-1499, 2015.
13. Bregendahl S, Emmertsen KJ, Lous J and Laurberg S: Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: A population-based cross-sectional study. Colorectal Dis 15: 1130-1139, 2013.
14. Cheong C, Oh SY, Choi SJ and Suh KW: Ultralow anterior resection and coloanal anastomosis for low-lying rectal cancer: An appraisal based on bowel function. Dig Surg 36: 409-417, 2019.
15. Ekkarat P, Boonpipattanapong T, Tantiphlachiva K and Sangkhathat S: Factors determining low anterior resection syndrome after rectal cancer resection: A study in Thai patients. Asian J Surg 39: 225-231, 2016.
16. Emmertsen KJ and Laurberg S; Rectal Cancer Function Study Group: Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg 100: 1377-1387, 2013.
17. Jimenez-Gomez LM, Espin-Basany E, Trenti L, Martí-Gallostra M, Sánchez-García JL, Vallribera-Valls F, Kreisler E, Biondo S and Armengol-Carrasco M: Factors associated with low anterior resection syndrome after surgical treatment of rectal cancer. Colorectal Dis: Sep 29, 2017 (Epub ahead of print).

18. Rosen H, Sebesta CG and Sebesta C: Management of Low Anterior Resection Syndrome (LARS) Following Resection for Rectal Cancer. Cancers (Basel) 15: 778, 2023

19. Qin Q, Huang B, Cao W, Zhou J, Ma T, Zhou Z, Wang J and Wang L: Bowel dysfunction after low anterior resection with neoadjuvant chemoradiotherapy or chemotherapy alone for rectal cancer: A cross-sectional study from China. Dis Colon Rectum 60: 697-705, 2017.

20. Sun W, Dou R, Chen J, Lai S, Zhang C, Ruan L, Kang L, Deng Y, Lan P, Wang L and Wang J: Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and quality of life in rectal cancer: Post hoc analysis of a randomized controlled trial. Ann Surg Oncol 26: 746-755, 2019.

21. Hughes DL, Cornish J and Morris C; LARRIS Trial Management Group: Functional outcome following rectal surgery-predisposing factors for low anterior resection syndrome. Int J Colorectal Dis 32: 691-697, 2017.

22. van Heinsbergen M, Janssen-Heijnen ML, Leijtens JW, Slooter GD and Konsten JL: Bowel dysfunction after sigmoid resection underestimated: Multicentre study on quality of life after surgery for carcinoma of the rectum and sigmoid. Eur J Surg Oncol 44: 1261-1267, 2018.

23. Kupsch J, Jackisch T, Matzel KE, Zimmer J, Schreiber A, Sims A, Witzigmann H and Stelzner S: Outcome of bowel function following anterior resection for rectal cancer-an analysis using the low anterior resection syndrome (LARS) score. Int J Colorectal Dis 33: 787-798, 2018.

24. Asnong A, Tack J, Devoogdt N, De Groef A, Geraerts I and D'Hoore A: Exploring the pathophysiology of LARS after low anterior resection for rectal cancer with high-resolution colon manometry. Neurogastroenterol Motil 34: e14432, 2022.

25. Eid Y, Bouvier V, Dejardin O, Menahem B, Chaillot F, Chene Y, Dutheil JJ, Juul T, Morello R and Alves A: 'French LARS score': Validation of the French version of the low anterior resection syndrome (LARS) score for measuring bowel dysfunction after sphincter-preserving surgery among rectal cancer patients: A study protocol. BMJ Open 10: e034251, 2020.

26. Tanaka N, Mizuno R, Ito K, Shirotake S, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, *et al*: External validation of the MSKCC and IMDC risk models in patients treated with targeted therapy as a first-line and subsequent second-line treatment: A Japanese multi-institutional study. Eur Urol Focus 2: 303-309, 2016.

27. Yu C, Liang H, Wang B, Liang F, Liu E and Xiang N: The association between reproductive history and the multidimensional health of older adults in rural China and its gender differences: Evidence from the Chinese longitudinal healthy longevity survey. Front Public Health 10: 952671, 2022.

28. Shabanian S, Khazaie M, Ferns GA and Arjmand MH: Local renin-angiotensin system molecular mechanisms in intrauterine adhesions formation following gynecological operations, new strategy for novel treatment. J Obstet Gynaecol 42: 1613-1618, 2022.

29. Chi P and Wang XJ: Significance of the intact of the fascia propria in protection of pelvic plexus during total mesorectal excision. Zhonghua Wei Chang Wai Ke Za Zhi 24: 297-300, 2021 (In Chinese).

30. Xu J, Tang B, Li T, Jia B, Yao H, Zhao R, Yuan W, Zhong M, Chi P, Zhou Y, *et al*: Robotic colorectal cancer surgery in China: A nationwide retrospective observational study. Surg Endosc 35: 6591-6603, 2021.

31. He S, Zhang J, Wang R, Li L, Shi L, Ren D, Wang J, Deng Y and Dou R: Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and stoma status in rectal cancer: Long-term functional follow-up of a randomized clinical trial. BJS Open 6: zrac127, 2022.

32. Zhang Q, An L, Yu R, Peng J, Yu K, Huang M, Li L and Wang X: The impact of neoadjuvant chemotherapy on low anterior resection syndrome after rectal cancer resection: A 6 Months longitudinal follow-up. Asian J Surg 44: 1260-1265, 2021.

33. Li YH, Qiu XY, Lin GL, Zhou JL, Xiao Y and Qiu HZ: Prognosis and complications of local excision for rectal cancer after neoadjuvant chemoradiotherapy. Zhonghua Wei Chang Wai Ke Za Zhi 24: 344-351, 2021 (In Chinese).

34. Shen D, Luo J, Chen L, Ma W, Mao X, Zhang Y, Zheng J, Wang Y, Wan J, Wang S, *et al*: PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer. Cancer Lett 550: 215919, 2022.

35. Wang L and Ma T: Cross suture closure technique of the perineal wound following abdominoperineal resection. Zhonghua Wei Chang Wai Ke Za Zhi 21: 936-939, 2018.

36. Cianci R, Cristel G, Agostini A, Ambrosini R, Calistri L, Petralia G and Colagrande S: MRI for rectal cancer primary staging and restaging after neoadjuvant chemoradiation therapy: How to do it during daily clinical practice. Eur J Radiol 131: 109238, 2020.

37. Knol J and Keller DS: Total mesorectal excision technique-past, present, and future. Clin Colon Rectal Surg 33: 134-143, 2020.

38. Pandit N, Deo KB, Gautam S, Yadav TN, Kafle A, Singh SK and Awale L: Extended total mesorectal excision (e-TME) for locally advanced rectal cancer. J Gastrointest Cancer 53: 253-258, 2022.

39. Pieniowski EHA, Nordenvall C, Palmer G, Johar A, Tumlin Ekelund S, Lagergren P and Abraham-Nordling M: Prevalence of low anterior resection syndrome and impact on quality of life after rectal cancer surgery: Population-based study. BJS Open 4: 935-942, 2020.